

Swedish Academy of Pharmaceutical Sciences

## The 5<sup>th</sup> conference on Clinical Trials in the Nordic Countries

15-16 June, 2016, Clarion Sign Hotel, central Stockholm

## www.lakemedelsakademin.se/CTNC2016

Time	Preliminary programme
	June 15th , Wednesday
10.00	Welcome, short intro
	Chairman: Mia Bengtström, Senior advisor, Pharma Industry Finland
	The EU Regulation 536/2014
	Implementation of the Regulation – EMA perspective
	Ana Rodriguez, Head of Clinical and Non-clinical Compliance, the European Medicines
	Agency
	Why regulation instead of directives?
	Implementation of the regulation from EMA point of view.
	Overview of the structure of the new database – overview of different working groups and procedures.  Overview of the application Procedures
	Implementation of the Regulation – Pharmaceutical industry perspectives.
	Nick Sykes, Senior Director, Worldwide Safety and Regulatory, Pfizer
	New guidelines under Eudralex volume 10 and upcoming reflection papers
	Ana Rodriguez, Head of Clinical and Non-clinical Compliance, the European Medicines
	Agency
	The Inspectors Working Group at EMA have published a number of reflection papers.
	What happens to these reflection papers when the new regulation comes in force?
11.50	Lunch
18.00	Chairman: Helena Lomberg, BCT Consulting, the Swedish Society for Clinical Trials
	Implementation of the Regulation in the Nordic countries; local perspectives
	National Competent Authorities and Ethics Committees representatives from the Nordic Countries will
	present the current status of the upcoming regulation with focus on local organizational aspects and
	procedures. What changes are to be expected? Collaboration between EC and CA? Main challenges? Which
	local laws will be affected? Communication strategy etc?
	There will be plenty of room for questions and discussions.
	<b>DK</b> : Lene Grejs Petersen, Senior Advisor, the Danish Medicines Agency and Karen Kiilerich, National Ethics Committee
	FI: Johanna Honkalammi, Senior Medical Officer, the Finnish Medicines Agency and Outi
	Konttinen, General Secretary, National Ethics Committee
	Coffee break
	NO: Ingvild Aaløkken, Head of Unit, the Norwegian Medicines Agency
	SE: Gunilla Andrew-Nielsen, Head of Clinical Trials, the Swedish Medical Products Agency
	and Peter Höglund, Professor, National Ethics Committee
	Short break
	Panel discussion: Q&A (All speakers day one)
	End of day one
10.00	End of day one
10.20	Conference dispar (concrete abaico sub se sesistarios)
18.30	Conference dinner (separate choice when registering)



## Swedish Academy of Pharmaceutical Sciences

Time	Topic
	June 16th, Wednesday
8.30	Chairman:
	Monika Larsen, Manager of R&D and Business Development, the Norwegian
	Association of Pharmaceutical Manufacturers
	Addendum for ICH GCP Guideline; status and changes
	Ana Rodriguez, Head of Clinical and Non-clinical Compliance, the European Medicines
	Agency
	The ICH GCP Guideline has been in force the last 20 years. An ICH Expert Working Group has been working
	on drafting an addendum to the guideline.  What are the changes in the addendum?
	What is the next steps and when will the addendum be in force?
	Coffee break
	Electronic systems in Clinical Trials, Lisbeth Bregnhøj, Medicines Inspector, the Danish
	Medicines Agency
	The expectations when it comes to electronic systems for handling source data, data collection tools, the
	use of interactive response technologies (IVRS / IWRS / IRT) and trial master files in clinical trials.
	Inspection findings – what can we learn?
	Philip Lange Møller, GCP Inspector, the Danish Medicines Agency, Helena Lindberg, GCP
	Inspector, the Swedish Medical Products Agency
11:30	Lunch
12:30	Panel discussion (All speakers from session before lunch)
	Chairman: Philip Lange Møller, GCP Inspector, the Danish Medicines Agency
	New initiatives to facilitate clinical trials in the Nordic countries
	– How are the Nordic countries attractive for clinical trials, and are competitive in a European
	setting?
	<b>SE:</b> National coordination of clinical studies in Sweden, Håkan Billig, Professor, Chair of
	Committee
	NO: Action plan for the Norwegian Health&Care 21 strategy, Maiken Engelstad,
	Assistant Director General , Norweigan Ministry of Health and Care Services
	<b>FI:</b> Secondary use of health data, Pekka Kahri, Director of Information Services, The
	National Institute for Health and Welfare, Finland
	Coffee break
15.15	Initiatives for cooperation between the Nordic Countries
	Nord Ped Med, Pirkko Lepola, University of Tampere
0.4633	
Ca 16.00	End of meeting